Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients with Refractory Malignancies
MD Anderson Study Status
The purposes of this trial are: - To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors. - To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors. Patients will receive QBI-139 by IV infusion over at least one hour once weekly for three weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients receive escalating doses of QBI-139 until the maximum tolerated dose (MTD) is determined.
Information and next steps
David Sanghyun Hong
Investigational Cancer Therapeutics
For general questions about clinical trials: